- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02157272
Rivaroxaban in Thrombotic Antiphospholipid Syndrome (TRAPS)
A Prospective, Randomized Clinical Trial Comparing Rivaroxaban vs Warfarin in High Risk Patients With Antiphospholipid Syndrome
Primary Study Objective(s) The primary objective is to demonstrate the non-inferiority of Rivaroxaban 20 mg (or 15mgqd in case of moderate renal insufficiency) versus warfarin (INR 2.0-3.0) with respect to the occurrence of the cumulative end point of incident acute thrombosis (arterial or venous) confirmed by appropriate imaging studies, major bleedings, and death in triple aPL-positive APS patients.
Study Design A multicentre, interventional, prospective, parallel, randomised, controlled, open-label, Rivaroxaban 20 mg qd (or 15mg qd in patients with moderate renal insufficiency) vs warfarin (INR target 2.5), non-inferiority study, in 535 triple aPL-positive APS patients in approximately 40 Internal Medicine and Thrombosis centres. Each local Institutional Review Board will approve the study.
Study Population Patients of both sexes, of age 18-75, affected by anti-phospholipid syndrome, with a high probability of recurrences as defined by triple aPL-positivity, are eligible for this study.
Primary Outcome variables The primary cumulative outcome measure will be incident acute thrombosis (arterial or venous) confirmed by appropriate imaging studies, major bleeding, or death.
Secondary Outcome variables Separate evaluation of arterial and venous thrombosis and all-cause death.
04.27.2015: An amendment has been made. Enrollment permitted till 75 years of age.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Padova, Italy, 35128
- University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed and dated informed consent form
- Male or female of age 18-75 years
Triple aPL-positivity in the last blood sampling defined as:
- aCL IgG/M (≥40 GPL or MPL, medium-to-high titer, and/or greater than the 99th percentile) and
- aB2GPI IgG/M (≥40 U, medium-to-high titer, and/or greater than the 99th percentile) and
- LA test positive based on the International Society of Thrombosis & Hemostasis Recommendations.
- Positivity of aCL and abeta2GPI must be of the same isotype.
- To confirm triple positivity for aPL and to validate the laboratory diagnosis, plasma (at least 2ml prepared by double centrifugation at 2000g) from patients of each Center will be stored at -80°C and later on sent in dry ice and retested in a reference laboratory (Padua Thrombosis Centre). Expenses for shipment will be in charge to the coordinator Center.
- History of thrombosis (objectively proven arterial, venous, and/or biopsy proven microthrombosis) and/or pregnancy morbidity according to Miyaki
Exclusion Criteria:
Subjects meeting any of the following criteria will not be enrolled in the study:
- Severe hypersensitivity reaction to rivaroxaban
- Calculated CLCR <30 mL/min at the screening visit
- Current pregnancy or breast feeding. Pregnancy is highly discouraged in these patients and if programmed patients are excluded from the study. If sexually active, be practicing an effective method of birth control (e.g., intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study
- Concomitant treatment with other anticoagulants, such as unfractionated heparin, low molecular weight heparins (enoxaparin, dalteparin, etc.) heparin derivatives (fondaparinux), other oral anticoagulants (dabigatran etexilate, apixaban) in the case they can not be substituted with the study drugs.
- Patients taking interfering medications: pharmacologic interactions may occur with strong inhibitors of p-glycoprotein and of CYP3A4, e.g., azole-antimycotics, such as ketoconazole, itraconazole, voriconazole, posaconazole, and HIV protease inhibitors; coadministration of rivaroxaban is therefore contraindicated in these cases. Several drugs used in neurological patients, such as phenobarbital, phenytoin, carbamazepine, and st john's wort (hypericum), are p-glycoprotein inducers and should be avoided. Whenever possible, it would be better to use levetiracetam and topiramate as antiepileptic therapy.
Hemorrhage Risk-Related Criteria
- History of or condition associated with increased bleeding risk including, but not limited to:
- Major surgical procedure or trauma within 30 days before the randomization visit
- Clinically significant gastrointestinal bleeding within 6 months before the randomization visit
- History of intracranial, intraocular, spinal, or atraumatic intra-articular bleeding
- Chronic hemorrhagic disorder
- Known intracranial neoplasm, arteriovenous malformation, or aneurysm
- Planned invasive procedure with potential for uncontrolled bleeding.
- Sustained uncontrolled hypertension: systolic blood pressure ≥180 mmHg
- Known liver cirrhosis or ALT above three times the upper normal value.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Rivaroxaban
Rivaroxaban 20mg qd, Rivaroxaban 15mg qd if creatinine clearance between 30-49 ml/min (calculated by Cockroft-Gault equation)
|
The investigated drug is Rivaroxaban 20mg, a film coated tablet, which is a highly selective direct factor Xa inhibitor.
It should be administered orally, every day at any time (always the same), with food.
The treatment should be performed for all the treatment period.
Other Names:
|
ACTIVE_COMPARATOR: Warfarin
To Keep an INR between 2.0 and 3.0
|
The investigated drug is Rivaroxaban 20mg, a film coated tablet, which is a highly selective direct factor Xa inhibitor.
It should be administered orally, every day at any time (always the same), with food.
The treatment should be performed for all the treatment period.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cumulative outcome measure will be incident acute thrombosis (arterial or venous) confirmed by appropriate imaging studies, major bleeding, or death.
Time Frame: up to 4 years
|
up to 4 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
• Any single type of thromboembolic event
Time Frame: up to 4 years
|
up to 4 years
|
All-cause mortality
Time Frame: up to 4 years
|
up to 4 years
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EUDRACT 2013-004575-13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antiphospholipid Syndrome
-
Cairo UniversityCompletedPrimary Antiphospholipid SyndromeEgypt
-
University of FloridaHoffmann-La RocheCompletedAntiphospholipid Antibody SyndromeUnited States
-
Hospital Universitario Pedro ErnestoCompletedAntiphospholipid Antibody Syndrome
-
Italian Society for RheumatologyRecruitingAntiphospholipid Syndrome | Seronegative Antiphospholipid SyndromeItaly
-
Duke UniversityRecruitingAntiphospholipid SyndromeUnited States
-
Yale UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Hospital for...Active, not recruitingAntiphospholipid Syndrome (APS)United States
-
Richard Burt, MDWithdrawnANTIPHOSPHOLIPID SYNDROMEUnited States
-
Ruijin HospitalRecruitingAntiphospholipid Syndrome (APS)China
-
University Hospital, RouenUnknownAntiphospholipid Syndrome (APS)France
-
University Hospital, AngersUnknownPrimary Antiphospholipid SyndromeFrance
Clinical Trials on Experimental: Rivaroxaban
-
Assistance Publique - Hôpitaux de ParisBayer; Action Research GroupCompletedHemorrhage | Atrial Fibrillation | Atrial AppendageFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHPV | Related Malignancy | Related CarcinomaUnited States
-
Wake Forest University Health SciencesMichael J. Fox Foundation for Parkinson's ResearchWithdrawn
-
Piedmont HealthcareLivaNovaCompletedHeart FailureUnited States
-
Finis Terrae UniversityNot yet recruitingPostoperative Pain | Respiratory ComplicationChile
-
Polish Mother Memorial Hospital Research InstituteCompletedBottle Feeding | PrematurePoland
-
University of Illinois at ChicagoRecruiting
-
Le Mans UniversiteActive, not recruiting
-
Aston UniversityBirmingham Women's and Children's NHS Foundation TrustRecruitingReflex Epilepsy, Photosensitive | EyeglassesUnited Kingdom
-
University Hospital, MontpellierCompletedNon-valvular Atrial FibrillationFrance